Kurt J. Hilzinger, Director at Outlook Therapeutics, Inc. (OTLK), bought 130,595 shares at $1.25 ($163K) on 2022-10-03, disclosed to the SEC on 2022-10-03.
Open-market purchase of $163k OTLK by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade B.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.19 | 13,800 | $16K | 10.1% |
| 2 | $1.26 | 33,199 | $42K | 25.7% |
| 3 | $1.25 | 41,798 | $52K | 32.1% |
| 4 | $1.25 | 41,798 | $52K | 32.1% |
| Total | $1.25 avg | 130,595 | $163K | 100% |
| Filing → |
| OTLK | BUY | 2022-03-03 | $47K | — | Filing → |
| OTLK | BUY | 2022-02-28 | $130K | — | Filing → |
| OTLK | BUY | 2022-02-23 | $514K | — | Filing → |